Ventyx Biosciences: Strong Financial Position and Promising Pipeline Drive Buy Rating
Canaccord Genuity analyst Edward Nash has maintained their bullish stance on VTYX stock, giving a Buy rating on November 8. Edward ...
Ventyx Biosciences (VTYX) Gets a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...
Ventyx Biosciences files offering of common stock
Ventyx Biosciences (NASDAQ:VTYX) files prospectus the offer and resale from time to time of up to 7,060,100 shares of common stock. SEC Filing More on Ventyx Biosciences Ventyx Biosciences: R ...
manilatimes4d
Jushi Holdings Inc. Reports Third Quarter 2024 Financial Results
Revenue in Q3 2024 decreased by $3.8 million to $61.6 million as compared to $65.4 million in Q3 2023. The year-over-year decrease in revenue can primarily be attributed to a decrease in retail ...
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
Topline results from the Phase 2a trial of VTX3232 in patients with early Parkinson’s disease expected in H1 2025 Phase 2 trial of VTX3232 in subjects with obesity and cardiometabolic risk factors ...